These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 11421867)

  • 1. The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects-male and female, elderly and young.
    Appel-Dingemanse S; Horowitz A; Campestrini J; Osborne S; McLeod J
    Aliment Pharmacol Ther; 2001 Jul; 15(7):937-44. PubMed ID: 11421867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tegaserod pharmacokinetics are similar in patients with severe renal insufficiency and in healthy subjects.
    Swan SK; Zhou H; Horowitz A; Alladina L; Hubert M; Appel-Dingemanse S; Osborne S; Lambrecht L; McLeod JF
    J Clin Pharmacol; 2003 Apr; 43(4):359-64. PubMed ID: 12723456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects.
    Zhou H; Horowitz A; Ledford PC; Hubert M; Appel-Dingemanse S; Osborne S; McLeod JF
    J Clin Pharmacol; 2001 Oct; 41(10):1131-9. PubMed ID: 11583482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity.
    Appel-Dingemanse S
    Clin Pharmacokinet; 2002; 41(13):1021-42. PubMed ID: 12403641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919).
    Appel-Dingemanse S; Hirschberg Y; Osborne S; Pommier F; McLeod J
    Eur J Clin Pharmacol; 2001 Mar; 56(12):889-91. PubMed ID: 11317476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of age and gender on the single dose pharmacokinetics of avitriptan administered to healthy volunteers.
    Marathe PH; Greene DS; Kollia GD; Barbhaiya RH
    J Clin Pharmacol; 1997 Oct; 37(10):937-45. PubMed ID: 9505985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tegaserod coadministration does not alter the pharmacokinetics of theophylline in healthy subjects.
    Zhou H; Khalilieh S; Svendsen K; Pommier F; Osborne S; Appel-Dingemanse S; Lasseter K; McLeod JF
    J Clin Pharmacol; 2001 Sep; 41(9):987-93. PubMed ID: 11549104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers.
    Tarral A; Merdjan H
    Clin Ther; 2015 Apr; 37(4):877-86. PubMed ID: 25769615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial.
    Foxx-Orenstein AE; Camilleri M; Szarka LA; McKinzie S; Burton D; Thomforde G; Baxter K; Zinsmeister AR
    Neurogastroenterol Motil; 2007 Oct; 19(10):821-30. PubMed ID: 17539894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects.
    Degen L; Matzinger D; Merz M; Appel-Dingemanse S; Osborne S; Lüchinger S; Bertold R; Maecke H; Beglinger C
    Aliment Pharmacol Ther; 2001 Nov; 15(11):1745-51. PubMed ID: 11683688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome.
    Hasler WL; Schoenfeld P
    Drug Saf; 2004; 27(9):619-31. PubMed ID: 15230644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, SUVN-502, in Healthy Young Adults and Elderly Subjects.
    Nirogi R; Mudigonda K; Bhyrapuneni G; Muddana NR; Goyal VK; Pandey SK; Palacharla RC
    Clin Drug Investig; 2018 May; 38(5):401-415. PubMed ID: 29380267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tegaserod does not alter fasting or meal-induced biliary tract motility.
    Fisher RS; Thistle J; Lembo A; Novick J; O'Kane P; Chey WD; Beglinger C; Rueegg P; Shi V; Dogra A; Luo D; Earnest DL
    Am J Gastroenterol; 2004 Jul; 99(7):1342-9. PubMed ID: 15233676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of age on the pharmacokinetics of naftidrofuryl after single oral administration in elderly versus young healthy volunteers.
    Hulot T; Gamand S; Dupain T; Ahtoy P; Bromet M
    Arzneimittelforschung; 1998 Sep; 48(9):900-4. PubMed ID: 9793615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects.
    Rohatagi S; Gillen M; Aubeneau M; Jan C; Pandit B; Jensen BK; Rhodes G
    Int J Clin Pharmacol Ther; 2001 Mar; 39(3):126-34. PubMed ID: 11396753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects.
    Behm MO; Yee KL; Fan L; Fackler P
    Antivir Ther; 2017; 22(4):337-344. PubMed ID: 28206979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome.
    Tougas G; Snape WJ; Otten MH; Earnest DL; Langaker KE; Pruitt RE; Pecher E; Nault B; Rojavin MA
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1701-8. PubMed ID: 12269961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects.
    Morganroth J; Rüegg PC; Dunger-Baldauf C; Appel-Dingemanse S; Bliesath H; Lefkowitz M
    Am J Gastroenterol; 2002 Sep; 97(9):2321-7. PubMed ID: 12358251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tegaserod: a new 5-HT4 agonist.
    Lacy BE; Yu S
    J Clin Gastroenterol; 2002 Jan; 34(1):27-33. PubMed ID: 11743242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study.
    Sikes C; Stark JG; McMahen R; Engelking D
    Clin Ther; 2017 Dec; 39(12):2389-2398. PubMed ID: 29174216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.